India, June 24 -- Biocon Limited has reinforced its commitment to diabetes care in Malaysia after its long-term partner, Duopharma Biotech Berhad, secured multiple insulin supply contracts from Malaysia's Ministry of Health (MoH) valued at over MYR 225 million.
Under the agreements, Biocon's Malaysian subsidiary, Biocon Sdn. Bhd., will supply recombinant human insulin, insulin glargine, and insulin aspart to Duopharma for distribution across the country, helping ensure continued access to affordable and high-quality insulin therapies.
The contracts include a three-year agreement worth approximately MYR 155.27 million for human insulin, along with two-year contracts worth MYR 18 million for insulin glargine and MYR 52.5 million for insulin...